|
Title
|
|
|
|
Long-term survival after progressive multifocal leukoencephalopathy in a patient with primary immune deficiency and NFKB1 mutation
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| Purpose To describe the development of progressive multifocal leukoencephalopathy (PML) in a patient with primary immune deficiency (PID) due to aNFKB1(nuclear factor kB subunit 1) mutation, who was treated successfully with a combination of mirtazapine and mefloquine. Methods We've based the treatment of our patient on literature research and provide a review of PML in CVID patients. Results Only a few reports have been published on the occurrence of PML in PID. PML is mainly observed in patients with reduced cellular immunity, which was not the case in our patient. Successful treatment options in this population are limited. Though severely disabled, our patient still survives, more than 4 years after symptom onset and shows consistent improvement on MRI (magnetic resonance imaging) and CSF (cerebrospinal fluid) analysis. Conclusion We conclude that some patients with PML might be treatable and can show long-term survival although neurological deficits remain. Involvement of humoral immunity in the pathogenesis of PML as well as the possible role of NFKB1 mutations in response to specific pathogens deserves further investigation. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
Journal of clinical immunology. - New York, N.Y., 1981, currens
|
|
|
Publication
|
|
|
|
New york
:
Springer/plenum publishers
,
2020
|
|
|
ISSN
|
|
|
|
0271-9142
[print]
1573-2592
[online]
|
|
|
DOI
|
|
|
|
10.1007/S10875-020-00862-Y
|
|
|
Volume/pages
|
|
|
|
p. 1-6
|
|
|
ISI
|
|
|
|
000568493000001
|
|
|
Pubmed ID
|
|
|
|
32918165
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|